Four months after emerging from stealth with FDA clearance of the Ampa One system and an oversubscribed $8.5 million round led by Nexus NeuroTech Ventures, Ampa announced its nationwide rollout. This milestone marks a major step in bringing advanced, non-invasive brain stimulation to patients across the country.